Source: Aurora Spine Corporation.
Market Herald logo

Find out more about this capital raise

Be the first with the news that moves the market
  • Aurora Spine Corporation (ASG) has announced a C$6.5 million private placement with institutional investors
  • 11,220,930 units will be issued at a price of $0.58 per common share and associated common warrant
  • It expects the closing date to occur on or about September 17, 2021
  • Aurora Spine Corporation brings new solutions to the spinal implant market through minimally invasive regenerative spinal implant technologies
  • Aurora Spine Corporation (ASG) closed down by 10.94 per cent trading at $0.57 per share

Aurora Spine Corporation (ASG) has announced a C$6.5 million private placement with institutional investors.

It will issue up to 11,220,930 units priced at $0.58 per common share and associated common warrant.

Each warrant entitles the holder to purchase one common share for $0.75 for up to three years after the closing of the offering.

Aurora expects the closing date to occur on or about September 17, 2021.

Aurora will offer shares and warrants in the United States on a private placement basis pursuant to exemptions from the registration requirements of the United States Securities Act of 1933.

No securities will be sold or offered for sale in Canada.

Aurora Spine Corporation brings new solutions to the spinal implant market through minimally invasive regenerative spinal implant technologies.

Aurora Spine Corporation (ASG) closed down by 10.94 per cent trading at $0.57.

More From The Market Herald
Small Pharma - CEO, George Tziras.

" Small Pharma (TSXV:DMT) announces NCIB

Small Pharma (DMT) has received TSXV approval for a normal course issuer bid.
High Tide - CEO, Raj Grover.

" High Tide (TSXV:HITI) secures commitment for $19M credit facility

High Tide (HITI) has signed a binding commitment letter with Connect First Credit Union.
Spectral Medical Inc. - CMO, Dr. John Kellum

" Spectral (TSX:EDT) gets FDA approval for Tigris trial

Spectral Medical (EDT) announced that the U.S. Food and Drug Administration (FDA) has approved ten new clinical trial sites for the Tigris trial.

" Diagnos (TSXV:ADK) receives approval for its AI enabled Pathology Detection Systems

Diagnos (ADK) has received approval from the Costa Rican regulatory agency for its Artificial Intelligence (AI) enabled Pathology Detection Systems.